Medicure Inc. (MPH.V) TSXV

1.20

+0.08(+7.14%)

Updated at September 08 03:22PM

Currency In CAD

Medicure Inc.

Address

2-1250 Waverley Street

Winnipeg, MB R3T 6C6

Canada

Phone

204 487 7412

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

25

First IPO Date

September 06, 2012

Key Executives

NameTitlePayYear Born
Dr. Albert David Friesen Ph.D.Founder, Chief Executive Officer & Chairman of the Board283,8001947
Mr. Haaris Uddin B.Com., CPAChief Financial Officer118,000N/A
Dr. Reuben Saba Ph.D.Vice President of Scientific & Medical Affairs151,000N/A
Dr. Neil Owens Ph.D.President & Chief Operating Officer236,500N/A

Description

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.